title: Latanoprost nonresponders with open-angle glaucoma in the Japanese population.
abstract: OBJECTIVE
  As some patients show little response to latanoprost, one of the most powerful topical glaucoma medications, we investigated the incidence and clinical profiles of latanoprost nonresponders (LNR) in the Japanese population.
  
  
  METHODS
  We examined 62 glaucoma patients (62 eyes) who had received only latanoprost for more than 3 months. Their mean age was 63.8 +/- 1.8 years; the mean observation period was 9.7 +/- 0.4 months. At 1, 3, 6, and 12 months, their intraocular pressure (IOP) was measured, and the IOP reduction rate (RR) and the rate of LNR, defined as RR of 10% or less, were calculated. We statistically analyzed clinical factors involved in the LNR status of our study population.
  
  
  RESULTS
  At 1, 3, 6, and 12 months, RR was 20.1 +/- 2.0%, 18.8 +/- 2.3%, 21.1 +/- 2.8%, and 23.0 +/- 2.6%, respectively. At the same time points, the LNR incidence was 23.1%, 28.1%, 23.5%, and 31.8%, respectively, and significantly higher in patients whose baseline IOP was less than 15 mmHg. Patient sex and age and the glaucoma type played no significant role in the LNR status.
  
  
  CONCLUSIONS
  The incidence of LNR in the Japanese population, including normal-tension glaucoma (NTG) patients, is higher than among European or American patients. Only low baseline IOP was a significant clinical factor among LNR.
authors.affiliation: Department of Ophthalmology, Kyoto Prefectural University of Medicine, Kyoto, Japan. yikeda@ophth.kpu-m.ac.jp
authors.forename: Yoko
authors.initials: Y
authors.lastname: Ikeda
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Mori
authors.forename: Takeshi
authors.initials: T
authors.lastname: Ishibashi
authors.forename: Shigeta
authors.initials: S
authors.lastname: Naruse
authors.forename: Nobuko
authors.initials: N
authors.lastname: Nakajima
authors.forename: Shigeru
authors.initials: S
authors.lastname: Kinoshita
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D005902:Glaucoma, Open-Angle / Q000188:drug therapy* / Q000453:epidemiology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects; D007564:Japan / Q000453:epidemiology; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use*; D012189:Retrospective Studies; D017211:Treatment Failure
chemical_list: D000959:Antihypertensive Agents; D009883:Ophthalmic Solutions; D011461:Prostaglandins F, Synthetic; D000077338:Latanoprost